Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 2

Status

Completed 8Active not recruiting 6

Sponsor Class

INDUSTRY 8

Study Type

Interventional 8

Sponsor

Cancer Type

Gastrointestinal 4Breast 4CNS 1

Conditions

Stomach Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Breast Neoplasms 3HER2+ Metastatic Breast Cancer (MBC) 1Brain Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 30Cisplatin 20Carboplatin 20Paclitaxel 18Dexamethasone 14Pemetrexed 13Nivolumab 13Ipilimumab 12Fluorouracil 11Cyclophosphamide 11Gemcitabine 10Trastuzumab 9Docetaxel 9Cytarabine 9atezolizumab 8Rituximab 8Capecitabine 8daratumumab 7Doxorubicin 7zanubrutinib 6Prednisone 6Lenalidomide 6Daunorubicin 6venetoclax 5trametinib 5nilotinib 5ibrutinib 5fludarabine 5dabrafenib 5Bortezomib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Completed × Has announcements × Capecitabine × Clear all
NCT03675737 2026-02-27

KEYNOTE-859

Merck Sharp & Dohme LLC

Phase 3 Completed
1,579 enrolled 31 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03615326 2025-12-11

MK-3475-811

Merck Sharp & Dohme LLC

Phase 3 Completed
738 enrolled 22 charts 3 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT02872116 2025-08-07

CheckMate649

Bristol-Myers Squibb

Phase 3 Completed
2,031 enrolled 19 charts 1 FDA
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT03901339 2024-10-21

TROPiCS-02

Gilead Sciences

Phase 3 Completed
543 enrolled 25 charts 1 FDA
Breast

Breast Neoplasms

NCT02614794 2023-08-14

HER2CLIMB

Seagen Inc.

Phase 2 Completed
612 enrolled 30 charts 1 FDA
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT02335411 2022-08-08

KEYNOTE-059

Merck Sharp & Dohme LLC

Phase 2 Completed
318 enrolled 24 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT02574455 2022-06-15

ASCENT

Gilead Sciences

Phase 3 Completed
529 enrolled 23 charts 1 FDA
Breast

Breast Neoplasms

NCT01808573 2021-06-11

NALA

Puma Biotechnology, Inc.

Phase 3 Completed
621 enrolled 21 charts 1 FDA
Breast

HER2+ Metastatic Breast Cancer (MBC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡